Current Report Filing (8-k)
December 11 2017 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 11, 2017 (December 10, 2017)
Kadmon Holdings, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-37841
|
|
27-3576929
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
450
East 29
th
Street
New
York, NY
|
|
10016
|
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code (212) 308-6000
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
|
|
|
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
On December
10, 2017, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing additional encouraging findings
from an ongoing Phase 2 clinical trial demonstrating that KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, was
well tolerated and resulted in clinically meaningful responses in patients with chronic graft-versus-host disease (cGVHD). The
results were presented in a poster at the 59
th
American Society of Hematology (ASH) Annual Meeting in Atlanta (Poster
#3256). The full text of the press release and a copy of the poster are attached to this Current Report on Form 8-K as Exhibits
99.1 and 99.2, respectively, and are incorporated herein by reference.
|
|
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kadmon Holdings, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
Date: December 11, 2017
|
|
|
|
/s/
Konstantin Poukalov
|
|
|
|
|
|
Konstantin Poukalov
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Apr 2023 to Apr 2024
